Equities

Insmed Inc

Insmed Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)73.54
  • Today's Change1.85 / 2.58%
  • Shares traded1.12m
  • 1 Year change+209.64%
  • Beta1.0981
Data delayed at least 15 minutes, as of Nov 08 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Insmed Incorporated is a global biopharmaceutical company. The Company's first commercial product, ARIKAYCE (amikacin liposome inhalation suspension), is used for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Its pipeline includes clinical-stage programs, brensocatib and TPIP, as well as other early-stage research programs. Brensocatib is a small molecule, oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1), which is developing for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases, including chronic rhinosinusitis without nasal polyps (CRSsNP). TPIP is an inhaled formulation of the treprostinil prodrug treprostinil palmitil, which offers a differentiated product profile for pulmonary hypertension associated with interstitial lung disease (PH-ILD) and pulmonary arterial hypertension (PAH).

  • Revenue in USD (TTM)342.96m
  • Net income in USD-864.29m
  • Incorporated1999
  • Employees912.00
  • Location
    Insmed Inc700 Us Highway 202/206BRIDGEWATER 08807United StatesUSA
  • Phone+1 (908) 977-9900
  • Websitehttps://insmed.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Exact Sciences Corp2.69bn-214.04m9.53bn6.50k--2.975,226.403.54-1.17-1.1714.7017.350.40895.4011.60414,204.30-3.25-9.71-3.58-10.6072.9674.10-7.95-28.211.93--0.4459--19.9340.6367.26---3.71--
Revolution Medicines Inc742.00k-567.06m10.17bn490.00--6.47--13,702.40-3.59-3.590.00479.340.0005--4.801,962.96-41.28-29.76-44.46-32.59-----76,423.31-606.93----0.00---67.27-10.50-75.46--38.82--
Exelixis Inc2.08bn466.92m10.35bn1.31k23.104.5520.934.971.571.576.927.960.70123.398.041,589,006.0015.738.8618.089.9196.2596.3022.4315.433.88--0.000.0013.6016.4713.98-21.343.98--
Charles River Lbrtrs ntrntl Inc4.06bn413.08m11.01bn20.00k26.892.9114.342.718.018.0178.6373.970.52038.275.23203,045.805.486.466.337.6235.9336.9910.5411.581.144.960.37840.003.8612.75-2.3916.6917.86--
Medpace Holdings Inc2.07bn365.57m11.28bn5.90k31.7712.7628.595.4511.4211.4264.7028.421.16--6.85350,994.3020.4813.9443.5123.1829.6928.8417.6615.23----0.00--29.1721.7615.2631.1717.99--
Tempus AI Inc640.44m-800.71m11.38bn2.30k--213.26--17.78-8.29-8.294.440.3459----------------53.18---116.06--2.55-14.950.891--65.85--20.35------
Sarepta Therapeutics Inc1.64bn121.85m11.62bn1.31k100.009.5172.387.081.221.2216.3012.790.4890.57034.351,248,362.003.63-21.634.38-25.7585.9286.657.43-77.053.03--0.5013--33.2632.8023.81--6.30--
BIO-TECHNE Corp1.17bn150.68m12.07bn3.10k80.805.6446.0610.300.94020.94027.2913.460.42672.155.47377,930.005.499.425.7710.0465.9367.2912.8621.413.2618.070.12322.791.9710.17-41.0711.8619.870.00
Neurocrine Biosciences, Inc.2.24bn385.90m12.73bn1.70k33.674.6830.935.683.733.7321.6726.870.70270.89014.991,602,000.0012.099.7714.6712.1998.5298.5117.2114.794.2610.280.00--26.7633.1361.6263.902.67--
Insmed Inc342.96m-864.29m13.16bn912.00--27.21--38.36-5.56-5.562.212.700.20310.88488.81376,050.40-51.17-40.96-59.16-46.8877.2577.99-252.01-212.925.99-18.410.6702--24.3998.78-55.66---2.15--
Vaxcyte Inc0.00-507.65m13.29bn254.00--3.88-----4.55-4.550.0027.470.00----0.00-20.08-34.22-20.95-37.21------------0.00-------80.00--107.28--
Summit Therapeutics Inc0.00-196.68m15.79bn105.00--36.04-----0.2768-0.27680.000.59410.00----0.00-54.53-77.32-71.71-86.35-------20,989.46----0.053---100.00---680.54---4.84--
ICON PLC8.31bn747.89m17.74bn42.25k23.901.8213.762.148.998.9999.87118.390.4852--2.99202,112.504.373.935.244.8029.6328.919.007.37--4.410.2599--4.8925.6221.1813.6723.79--
Moderna Inc5.08bn-2.22bn18.00bn5.60k--1.51--3.54-5.81-5.8113.1430.980.28832.442.96907,321.40-12.6220.95-15.5229.5178.43---43.7732.104.20--0.05210.00-64.45119.28-156.37--46.22--
Data as of Nov 08 2024. Currency figures normalised to Insmed Inc's reporting currency: US Dollar USD

Institutional shareholders

44.62%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 30 Jun 202415.56m9.05%
T. Rowe Price Associates, Inc. (IM)as of 30 Jun 202411.96m6.96%
BlackRock Fund Advisorsas of 30 Jun 202411.61m6.76%
Darwin Global Management Ltd.as of 23 Aug 20249.72m5.66%
Fidelity Management & Research Co. LLCas of 30 Jun 20246.43m3.74%
Capital Research & Management Co. (International Investors)as of 30 Jun 20245.87m3.42%
SSgA Funds Management, Inc.as of 30 Jun 20244.66m2.71%
Geode Capital Management LLCas of 30 Jun 20243.64m2.12%
RTW Investments LPas of 30 Jun 20243.64m2.12%
Baker Bros. Advisors LPas of 30 Jun 20243.58m2.08%
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.